Roundtable Roundup: First and Second Choices for Frontline RCC Therapy
During separate virtual live events, David A. Braun, MD, PhD, and Rana R. McKay, MD, surveyed oncologists on options for a patient with clear cell renal cell carcinoma (RCC) in the front line.
CASE SUMMARY
- A 59-year-old African American woman was diagnosed with a left renal mass.
- She underwent left radical nephrectomy in December 2019.
- Clear cell RCC
- T3aN0Mx, International Society of Urological Pathology grade 3
- Nine months later, she reported pain in hips and left chest.
- Radiographic diagnosis: stage IV RCC with osteolytic lesions in iliac crest and left fifth rib
- ECOG performance status: 1
- Laboratory results:
- Hemoglobin level: 11.1 g/dL
- Elevated liver function test results
- Mild hypercalcemia (10.8 mg/dL)
- Neutrophil and platelet counts: within normal limits
CASE UPDATE
The patient received nivolumab (Opdivo) plus ipilimumab (Yervoy).
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
